{"disease":{"id":"recurrent-ovarian-cancer","name":"recurrent ovarian cancer"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03564340","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":890,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03398655","title":"A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Vascular Biogenics Ltd. operating as VBL Therapeutics","has_results":false},{"nct_id":"NCT07286162","title":"Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04091204","title":"Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT03776812","title":"Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Corcept Therapeutics","has_results":true},{"nct_id":"NCT06560112","title":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06769425","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04348032","title":"Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":152,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03458221","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"Gynaecologisch Oncologisch Centrum Zuid","has_results":false},{"nct_id":"NCT02122185","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03618706","title":"Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":107,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06434610","title":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT05610735","title":"Combination Therapy for Recurrent Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Sham Sunder Kakar","has_results":false},{"nct_id":"NCT02889900","title":"Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00538031","title":"Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07454018","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05819060","title":"The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04734665","title":"Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07495384","title":"Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT07286240","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05311579","title":"Niraparib Plus Anlotinib for Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07462468","title":"A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04718740","title":"A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01853644","title":"Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT02849353","title":"Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT05942300","title":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Lan Coffman","has_results":false},{"nct_id":"NCT04720807","title":"Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07314619","title":"Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT04068974","title":"Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT02788708","title":"Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Floor Backes","has_results":false},{"nct_id":"NCT01281514","title":"A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT04457089","title":"Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Marc Goodman","has_results":false},{"nct_id":"NCT01962948","title":"Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":true},{"nct_id":"NCT01747798","title":"Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT03430518","title":"Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Amy Tiersten","has_results":false},{"nct_id":"NCT05270720","title":"Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT01536054","title":"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06107868","title":"Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06257758","title":"A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Valerio Therapeutics","has_results":false},{"nct_id":"NCT05130515","title":"Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03642990","title":"NR in Chemo-induced Peripheral Neuropathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Donna Hammond, PhD","has_results":true},{"nct_id":"NCT05700669","title":"Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Valerio Therapeutics","has_results":false},{"nct_id":"NCT07060365","title":"A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03632798","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Cordgenics, LLC","has_results":false},{"nct_id":"NCT05126342","title":"Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"AGO Research GmbH","has_results":false},{"nct_id":"NCT03025867","title":"Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Tesaro, Inc.","has_results":false}],"total":49},"guidelines":[],"source":"Drug Landscape verified database"}